WEKO3
アイテム
Management of high-risk prostate cancer: Radiation therapy and hormonal therapy
https://repo.qst.go.jp/records/46736
https://repo.qst.go.jp/records/46736a6b9d73d-d33b-4705-8546-b0957150e43f
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2014-03-05 | |||||
| タイトル | ||||||
| タイトル | Management of high-risk prostate cancer: Radiation therapy and hormonal therapy | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
Nomiya, Takuma
× Nomiya, Takuma× Tsuji, Hiroshi× Toyama, Shingo× Maruyama, Katsuya× Nemoto, Kenji× Tsujii, Hirohiko× Kamada, Tadashi× 野宮 琢磨× 辻 比呂志× 戸山 真吾× 丸山 克也× 辻井 博彦× 鎌田 正 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | The prognosis of high-risk prostate cancer is poor with a high mortality rate. The Radiation Therapy Oncology Group (RTOG) has performed dose-escalation studies of external beam radiation therapy (EBRT) and has developed high-precision radiation therapy (RT) methods such as intensity-modulated RT, carbon ion therapy, and proton beam therapy. High-dose rate brachytherapy (HDR-BT) is also studied as an option for high-risk prostate cancer treatment. Past clinical trials have suggested that the local control rate of high-risk prostate cancer improves with total EBRT dose, even for doses >70 Gy. Several randomized controlled trials, including RTOG 94-06, have shown significantly better prognoses with higher doses (>75 Gy) than with lower doses (<70 Gy). A proton beam therapy trial (PROG 95–09) also showed similar results. A phase II clinical trial (National Institute for Radiological Sciences, Japan; trial 9904) showed that carbon ion therapy resulted in very good biochemical recurrence-free survival rates among high-risk prostate cancer patients, demonstrating particle therapy to be a valid treatment option. RTOG 86-10 showed that short-term neo-adjuvant hormonal therapy (HT) was inadequate for high-risk prostate cancer but effective for intermediate-risk prostate cancer, whereas RTOG 92-02 and the European Organisation for Research and Treatment of Cancer (EORTC) 22863 showed significant improvements in the prognosis of high-risk groups receiving long-term (>2 years) HT combined with definitive RT. Further studies are warranted to elucidate optimal irradiation doses, HT treatment durations, and combination therapy schedules. | |||||
| 書誌情報 |
Cancer Treatment Reviews 巻 39, 号 8, p. 872-878, 発行日 2013-12 |
|||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 0305-7372 | |||||
| DOI | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.1016/j.ctrv.2013.04.003 | |||||
